Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idelalisib + fludarabine
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
idelalisib + fludarabine is a combination therapy regimen studied for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). It consists of idelalisib (Zydelig), a small molecule inhibitor of the delta isoform of phosphatidylinositol 3-kinase (PI3Kδ), and fludarabine (Fludara), a purine nucleoside analog chemotherapy. Idelalisib blocks the PI3Kδ signaling pathway, which is essential for the proliferation and survival of malignant B-cells. Fludarabine acts as a cytotoxic agent by inhibiting DNA synthesis and repair. This combination was evaluated in Phase I clinical trials to assess safety and efficacy in patients who had failed prior therapies, showing high overall response rates, although idelalisib's clinical development in combination with other agents has been complicated by safety signals in later-stage trials.
- Other names
- idelalisib and fludarabineZydelig + Fludara
02
Targets
POLA1 (DNA polymerase alpha)DNA-directed primase/polymerase protein (PrimPol)PIK3CD (Phosphatidylinositol 3-kinase delta)RRM1DNA
Beyond the preview
Go deeper on idelalisib + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idelalisib + fludarabine.